Latest news
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Leerink Partners to "Market Perform" - marketbeat.commarketbeat.com · Fri, 07 Aug 2026 13:09:52 GMTThe Opportunity for Innovation in Desmoid Tumors: A Framework Based on Unmet Need - Leerink PartnersLeerink Partners · Thu, 30 Jul 2026 13:58:57 GMTLeerink Partners report names Carterra a core enabler of the $7 B "Lab-in-the-Loop" antibody discovery market - News-MedicalNews-Medical · Mon, 27 Jul 2026 07:00:00 GMT